Erectile Dysfunction and Cardiovascular Disease

References

• . NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA. 1993;270:83–90
   PubMed Web of Science ®Google Scholar
• . Ayta IA, McKinlay JB, Krane RJ. The likely world-wide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(1):50–56
   PubMed Web of Science ®Google Scholar
• . Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151–157
   PubMed Web of Science ®Google Scholar
• . Feldman HA, Johannes CB, Derby CA,. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000; 30(4):328–338
   PubMed Web of Science ®Google Scholar
• . Kostis JB, Jackson G, Rosen R,. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005;96(12):1754–1755
   PubMedGoogle Scholar
• . Russell ST, Khandheria BK, Nehra A. Erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2004;79(6):782–794
   PubMedGoogle Scholar
• . Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006;3(1):28–36
   PubMed Web of Science ®Google Scholar
• . Aboseif SR, Lue TF. Haemodynamics of penile erection. Urol Clin North Am. 1988;15(1):1–7
   PubMed Web of Science ®Google Scholar
• . Beckman TJ, Abu-Lebdeh HS, Mynderse LA. Evaluation and medical management of erectile dysfunction. Mayo Clin Proc. 2006;81(3):385–390
   PubMedGoogle Scholar
• . Gazzaruso C, Solerte SB, Pujia A,. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol. 2008;51(21):2040–2044
   PubMedGoogle Scholar
• . DeBusk R, Drory Y, Goldstein I,. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol. 2000;86(2A):175–181
   PubMedGoogle Scholar
• . Inman BA, Sauver JL, Jacobson DJ,. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84(2):108–113
   PubMed Web of Science ®Google Scholar
• . Thompson IM, Tangen CM, Goodman PJ,. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294(23):2996–3002
   PubMed Web of Science ®Google Scholar
• . Schouten BW, Bohnen AM, Bosch JL,. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen study. Int J Impot Res. 2008;20(1):92–99
   PubMed Web of Science ®Google Scholar
• . Kaiser DR, Billups K, Mason C,. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol. 2004;43(2):179–184
   PubMed Web of Science ®Google Scholar
• . Miner MM, Kuritzky L. Erectile dysfunction: a sentinel marker for cardiovascular disease in primary care. Clev Clin J Med. 2007;74( suppl 3):S30–S37
   Google Scholar
• . De Angelis L, Margella MA, Siniscalchi M,. Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia. 2001;44(9):1155–1160
   PubMedGoogle Scholar
• . Miner MM. Erectile dysfunction and the “window of curability”: a harbinger of cardiovascular events. Mayo Clin Proc. 2009;84(2):102–104
   PubMed Web of Science ®Google Scholar
• . Lee JH, Ngengwe R, Jones P, Tang F, O'Keefe JH. Erectile dysfunction as a coronary artery disease risk equivalent. J Nucl Cardiol. 2008;15(6):800–803
   PubMedGoogle Scholar
• . Chew KK, Finn J, Stuckey B,. Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data study. J Sex Med. 2010;7(1 pt 1):192–202
   PubMedGoogle Scholar
• . Araujo AB, Hall SA, Ganz P,. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score? J Am Coll Cardiol. 2010;55(4):350–356
   PubMed Web of Science ®Google Scholar
• . Batty GD, Li Q, Czernichow S,; ADVANCE Collaborative Group. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. J Am Coll Cardiol. 2010;56(23):1908–1913
   PubMedGoogle Scholar
• . Janiszewski PM, Janssen I, Ross R. Abdominal obesity and physical inactivity are associated with erectile dysfunction independent of body mass index. J Sex Med. 2009;6(7):1990–1998
   PubMedGoogle Scholar
• . Montorsi P, Ravagnani PM, Galli S,. The triad of endothelial dysfunction, cardiovascular disease, and erectile dysfunction: clinical implications. Eur Urol. 2009;8:58–66
   Google Scholar
• . Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;163(3):788–791
   PubMed Web of Science ®Google Scholar
• . Davis RM. The Marlboro man needs Viagra. Tob Control. 1998;7(3):227
   PubMedGoogle Scholar
• . Goff DC, Gerstein HC, Ginsberg HN,; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12A):4i–20i
   Web of Science ®Google Scholar
• . Selvin E, Marinopoulos S, Berkenblit G,. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . O'Keefe JH, Abuannadi M, Lavie CJ,. Strategies for optimizing glycemic control and cardiovascular prognosis in type 2 diabetes mellitus. Mayo Clin Proc. 2011;86(2):128–138
   PubMed Web of Science ®Google Scholar
• . Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic coronary artery disease. Am J Cardiol. 2003;91(2):230–231
   PubMedGoogle Scholar
• . Ma RC, So WY, Yang X,. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol. 2008;51(21):2045–2050
   PubMed Web of Science ®Google Scholar
• . Burke JP, Jacobson DJ, McGree ME,. Diabetes and sexual dysfunction: results from the Olmstead County study of urinary symptoms and health status among men. J Urol. 2007;177(4):1438–1442
   PubMed Web of Science ®Google Scholar
• . Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731–1737
   PubMed Web of Science ®Google Scholar
• . Tostes RC, Carneiro FS, Lee JA,. Cigarette smoking and erectile dysfunction: focus on NO bioavailability and ROS generation. J Sex Med. 2008;5(6):1284–1295
   PubMed Web of Science ®Google Scholar
• . Mannino DM, Klevens RM, Flanders WD. Cigarette smoking: an independent risk factor for impotence? Am J Epidemiol. 1994;140:1003–1008
   PubMed Web of Science ®Google Scholar
• . He J, Reynolds K, Chen J,. Cigarette smoking and erectile dysfunction among Chinese men without clinical vascular disease. Am J Epidemiol. 2007;166(7):803–809
   PubMedGoogle Scholar
• . Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet. 1985;1(8422):181–184
   PubMed Web of Science ®Google Scholar
• . Musicki B, Liu T, Lagoda GA,. Hypercholesterolemia-induced erectile dysfunction: endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase. J Sex Med. 2010;7(9):3023–3032
   PubMedGoogle Scholar
• . Cardenas GA, Lavie CJ, Cardenas V,. The importance of recognizing and treating low levels of high-density Lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med. 2008;9(4):239–258
   PubMedGoogle Scholar
• . deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51(1):49–55
   PubMedGoogle Scholar
• . Wei M, Macera CA, Davis DR,. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol. 1994;140(10):930–937
   PubMedGoogle Scholar
• . Lavie CJ, Milani RV. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J Am Coll Cardiol. 2008;51(1):56–58
   PubMedGoogle Scholar
• . Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol. 2004;172(1):255–258
   PubMedGoogle Scholar
• . Dogru MT, Basar MM, Simsek A,. Effects of statin treatment on serum sex steroids levels and autonomic and erectile function. Urology. 2008;71(4):703–707
   PubMed Web of Science ®Google Scholar
• . Hall SA, Kupelian V, Rosen RC,. Is hyperlipidemia or its treatment associated with erectile dysfunction? Results from the Boston Area Community Health (BACH) Survey. J Sex Med. 2009;6(5):1402–1413
   PubMedGoogle Scholar
• . Carvajal A, Macias D, Sáinz M,. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf. 2006;29(2):143–149
   PubMedGoogle Scholar
• . Corona G, Boddi V, Balercia G,. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med. 2010;7(4 pt 1):1547–1556
   PubMedGoogle Scholar
• . Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol. 2004;171(6 pt 1):2341–2345
   PubMedGoogle Scholar
• . Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc. 2009;84(2):139–148
   PubMed Web of Science ®Google Scholar
• . Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253(22):3263–3268
   PubMed Web of Science ®Google Scholar
• . Milbank AJ, Montague DK. Surgical management of erectile dysfunction. Endocrine. 2004;23(2–3):161–165
   PubMedGoogle Scholar
• . Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol. 2003;92(9A):9M–18M
   PubMed Web of Science ®Google Scholar
• . McCullough AR, Barada JH, Fawzy A,. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60(2 suppl 2):28–38
   PubMedGoogle Scholar
• . Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397–1404
   PubMed Web of Science ®Google Scholar
• . Derry FA, Dinsmore WW, Fraser M,. Efficacy and safety of oral sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury. Neurology. 1998;51(6):1629–1633
   PubMedGoogle Scholar
• . Sanchez RA, Vidal J, Jaurequi ML,. Efficacy, safety and predictive factors of therapeutic success with sildenafil for erectile dysfunction in patients with different spinal cord injuries. Spinal Cord. 2001;39(12):637–643
   PubMedGoogle Scholar
• . Derry F, Hultling C, Seftel AD,. Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urology. 2002;60(2 suppl 2):49–57
   PubMedGoogle Scholar
• . Seidman SN, Roose SP, Menza MA,. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry. 2001;158(10):1623–1630
   PubMed Web of Science ®Google Scholar
• . Nurnberg HG, Seidman SN, Gelenberg AJ,. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology. 2002;60:58–66
   PubMed Web of Science ®Google Scholar
• . Zusman RM, Morales A, Glasser DB,. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83(5 A):35C–44C
   Google Scholar
• . Boolell M, Allen MJ, Ballard SA,. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8(2):47–52
   PubMedGoogle Scholar
• . DeBusk RF, Pepine CJ, Glasser DB,. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol. 2004;93(2):147–153
   PubMed Web of Science ®Google Scholar
• . Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens. 2001;14(1):70–73
   PubMed Web of Science ®Google Scholar
• . Stuckey BG, Jadzinsky MN, Murphy LJ,. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care. 2003;26(2):279–284
   PubMed Web of Science ®Google Scholar
• . Boulton AJ, Selam JL, Sweeney M,. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001;44(10):1296–1301
   PubMedGoogle Scholar
• . El-Sakka AI. Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol. 2004;46(4):503–509
   PubMed Web of Science ®Google Scholar
• . Kamel A, Khaouli R, Sabha M,. The real-life efficacy and safety of vardenafil: an international post-marketing surveillance study of 2824 patients from the Middle East. Clin Drug Investig. 2007;27(5):339–346
   PubMed Web of Science ®Google Scholar
• . Tobing NL, Arsyad KM, Manuputty D,. The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study from 1171 Indonesian patients. Maj Kedokt Indon. 2006;56(8):468–473
   Google Scholar
• . Padma-Nathan H, Porst H, Eardley I,. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Am J Hypertens. 2002;15:A48
   PubMed Web of Science ®Google Scholar
• . Goldstein I, Young JM, Fischer J,; Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3):777–783
   PubMed Web of Science ®Google Scholar
• . Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med. 2006;3(5):883–891
   PubMedGoogle Scholar
• . Sáenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002;25(12):2159–2164
   PubMed Web of Science ®Google Scholar
• . Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia. 2004;47(11):1914–1923
   PubMed Web of Science ®Google Scholar
• . Lewis RW, Sadovsky R, Eardley I,. The efficacy of tadalafil in clinical populations. J Sex Med. 2005;2(4):517–531
   PubMedGoogle Scholar
• . Ebrahim S, May M, Ben Shlomo Y,. Sexual intercourse and risk of ischaemic stroke and coronary heart disease: the Caerphilly study. J Epidemiol Community Health. 2002;56(2):99–100
   PubMed Web of Science ®Google Scholar
• . Hall SA, Shackelton R, Rosen RC, Araujo AB. Sexual activity, erectile dysfunction, and incident cardiovascular events. Am J Cardiol. 2010;105(2):192–197
   PubMed Web of Science ®Google Scholar
• . Muller JE, Mittleman MA, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA. 1996;275(18):1405–1409
   PubMedGoogle Scholar
• . Moller J, Ahlborn A, Hulting J,. Sexual activity as a trigger of myocardial infarction: a case-crossover analysis in the Stockholm Heart Epidemiology Program (SHEEP). Heart. 2001;86(4):387–390
   PubMedGoogle Scholar
• . Tofler GH, Muller JE. Triggering of acute cardiovascular disease and potential preventive strategies circulation. Circulation. 2006;114(17):1863–1872
   PubMedGoogle Scholar